Phase I Trial: Quotient Code QSC303820
This clinical trial, identified as Quotient Code QSC303820, is an early-stage study, known as Phase I. This means it's one of the first times a new treatment or medicine is being tested in a small group of people. The main goals at this stage are to understand if it's safe to use, to learn about any potential side effects, and to see how the body processes the new treatment. The specific health conditions or problems this study is trying to address, as well as more detailed information about the treatment itself, are not yet publicly available. This information will be released later, within 30 months after the study has officially concluded. Participants will be adults aged between 18 and 55, and the study is open to both men and women.
At a glance
What is this study about?
This study, known as Quotient Code QSC303820, is an early and important step in developing new medicines or treatments. It's called a 'Phase I' trial. Think of it like taking a new car design for its very first test drive – we want to make sure it's safe to be on the road.
In a Phase I trial, doctors and researchers are primarily focused on safety. They give a new treatment to a small group of healthy volunteers or people with a specific condition to see how their bodies react. They carefully watch for any side effects and learn how much of the treatment the body can handle without problems. They also find out how the body absorbs, uses, and gets rid of the treatment.
The specific details about what this particular treatment is for, or what health problems it aims to help with, are being kept private for now. This is quite common in early-stage trials. The full information will be made public within 30 months after the study has finished. This future release of information will help everyone understand the full purpose and findings of this important research.
Key takeaways
- This is an early-stage (Phase I) study testing a new treatment.
- The primary goal is to check the treatment's safety in people.
- Specific details about the treatment and its purpose are currently private.
- Full study details will be publicly released within 30 months after it concludes.
- Participants must be between 18 and 55 years old, male or female.
Who may be eligible?
To take part in this study, you need to be an adult between the ages of 18 and 55 years old, inclusive. Both men and women can participate.
At this stage, the study organisers are keeping more specific details about who can and cannot join private. This is sometimes done in early-phase trials. The full list of requirements will be made available to the public within 30 months after the study has officially ended.
Once the full details become available, there will be clearer guidelines explaining any specific health conditions, past medical treatments, or lifestyle factors that would either allow you to join (inclusion criteria) or prevent you from joining (exclusion criteria) the study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 55 years old?
- Are you male or female (the study is open to both)?
- Are you able to commit to potential appointments and monitoring?
- Are you comfortable with the fact that full study details are not yet public?
What does participation involve?
The public details about what exactly is involved in taking part in this specific study are not available yet. However, in a typical Phase I trial, participants can expect to:
* **Have initial screenings:** This involves medical tests, physical exams, and discussions about your health history to make sure you meet the study's requirements. * **Receive the study treatment:** This might be a new medicine in pill form, an injection, or a different type of treatment. You would be closely monitored. * **Attend regular visits:** You would likely have frequent appointments at the study clinic or hospital. During these visits, doctors and nurses will check your health, take vital signs, collect blood or urine samples, and ask about any symptoms or side effects you might be experiencing. * **Undergo assessments:** There might be various tests, scans, or questionnaires to assess how your body is reacting to the treatment. * **Have follow-up:** Even after the main treatment period, there might be follow-up appointments to monitor your long-term health and any lasting effects.
The total duration of your participation could range from several weeks to a few months, depending on the specific design of the study. More precise information on visits, medication, assessments, and total duration will be released when the full study details are published.
Potential risks and benefits
Locations (1)
- Quotient Sciences LimitedCity onlyNottingham, England
Common questions
What does 'Phase I Trial' mean?
It's the first stage of testing a new treatment in a small group of people. The main aims are to test its safety and see how the body handles it.
Why aren't all the details public yet?
Sometimes, in early research stages, information is kept private to protect the study or the developers. All details will be released within 30 months after the study ends.
Who can take part in this study?
Adults between 18 and 55 years old, both men and women, are eligible. More detailed health requirements will be shared later.
Will I know what the treatment is for?
Not right now. The specific health condition this study addresses and the treatment details are part of the information that will be released later.
Can I leave the study if I change my mind?
Yes, you always have the right to leave any clinical study at any time, without it affecting your standard medical care.
How to find out more
Kirsty Webster
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.